NCT07272512 2025-12-19
ZSPAC-17
Shanghai Zhongshan Hospital
Phase 4 Recruiting
Clinical Trials
7 trialsNCT06016855 2025-12-17
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 4 Recruiting
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT02779257 2022-03-04
Pasireotide Treatment for Neuroendocrine Tumor
University of Maryland, Baltimore
Phase 4 Withdrawn
NCT04140409 2019-10-25
SCIROCCO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 4 Terminated
NCT03083210 2019-05-20
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Samsung Medical Center
Phase 4 Unknown